Capivasertib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), G-BA (Germany) and NICE (England), among others, recommended or restricted capivasertib, while CIPM (Spain), DMC (Denmark) and SMC (Scotland) did not recommend it.
The record spans 2.2 years, opening at CHUIKYO (Japan) on 15 May 2024 and running to 24 Aug 2026.
PBAC (Australia) changed its position: not recommended in 2024, recommended by 2025, after a resubmission.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 10 of 11 records date from 2023 or later.
4 distinct indication wordings are recorded for capivasertib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 11 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CHUIKYO (Japan) was first to assess capivasertib, on 15 May 2024; TLV (Sweden) did not open a file until 24 Aug 2026 — a moderate spread of 2.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 10 dated records fall in 2025 alone.
2 of the 9 agencies here assessed capivasertib more than once, PBAC (Australia) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for capivasertib.
The full ledger for capivasertib reads 4 recommended, 4 not recommended, 1 restricted and 1 appraised, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 29 Oct 2025 | Til voksne patienter med østrogenreceptor (ER)-positiv, HER2-negativ lokalt fremskreden eller metastatisk brystcancer me… | Ikke anbefalet | source |
| SMC (Scotland) | 13 Oct 2025 | In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined… | not recommended | source |
| CIPM (Spain) | 16 Jul 2025 | Indicaciones terapéuticas autorizadas: TRUQAP está indicado en combinación con fulvestrant para el tratamiento de pacien… | not financed by the SNS · art. 92 d, e | source |
| PBAC (Australia) | 2025 | Hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) locally advanced (unresectable) or metastatic breast cancer | Recommended | source |
| NICE (England) | 15 May 2025 | NICE TA1063 | recommended (optimised) | source |
6 further decisions for capivasertib, across 5 agencies, are not shown here. They include the most recent record on file, 24 Aug 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 11 decisions for capivasertib from 9 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.